⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Switch Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Switch Therapeutics
↗South San Francisco, USA
Switch Therapeutics is a precision neuroscience biotechnology company pioneering a new class of RNA interference (RNAi) medicines. The company utilizes its proprietary Conditionally Activated siRNA (CASi) platform, which integrates nucleic acid nanotechnology and RNAi science to create molecules that are activated only in specific cell types. This approach aims to improve therapeutic windows and enable the treatment of central nervous system (CNS) diseases with high unmet needs.
Founded in 2020 based on research from Caltech, Harvard Medical School, and City of Hope, the company emerged from stealth in 2023 with significant venture backing. Switch is currently advancing a pipeline of neurodegenerative disease programs, including a lead candidate for Alzheimer's disease, and is focused on expanding its platform through internal development and potential pharmaceutical collaborations.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2020
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$71.9M
Investors:Insight Partners, UCB Ventures, Eli Lilly and Company, Upfront Ventures, BOLD Capital Partners, Ono Venture Investment, Digitalis Ventures, Dolby Family Ventures, Free Flow Ventures, PhiFund Ventures
PIPELINE
Stage:Preclinical
Lead Drug Stage:Preclinical (IND-enabling)
Modalities:RNAi, siRNA, Nanotechnology
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Scientific Advisory Board includes experts like Dr. David M. Holtzman
COMPETITION
Position:Emerging
Competitors:Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, Jazz Pharmaceuticals, Sana Biotechnology
LEADERSHIP
Key Executives:
Dee Datta - Co-Founder and CEO
Si-ping Han - Co-Founder and CTO
Brandi Simpson - SVP, Business Development
Scientific Founders:Si-ping Han, Dee Datta, Saumya Das
LINKS
Website:switchthera.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Switch Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.